Biosimilar Pipeline | Amgen Biosimilars
CLEAR

Our Pipeline

Inflammation

Oncology

Hematology

ABP 798 (biosimilar rituximab)

Anti-CD20 monoclonal antibody

ABP 959 (biosimilar eculizumab)

Monoclonal antibody that specifically binds to the complement protein C5

ABP 938 (biosimilar aflibercept)

A vascular endothelial growth factor (VEGF) inhibitor

Next: FDA-Approved Products Next: clinical trials